Clearside Biomedical Inc

NASDAQ:CLSDUnited States

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Contact Information

Headquarters

900 North Point Parkway, Suite 200ALPHARETTA, GA, United States 30005

Phone

678-270-3631

Fax

678-270-4033

Executives

Independent Chairman of the Board

Anthony Gibney

President, Chief Executive Officer, Director

George Lasezkay

Chief Financial Officer

Charles Deignan

Chief Medical Officer

Victor Chong

Independent Director

Richard Croarkin